» Articles » PMID: 30059813

Metabolic Fingerprinting in Breast Cancer Stages Through H NMR Spectroscopy-based Metabolomic Analysis of Plasma

Overview
Specialty Chemistry
Date 2018 Jul 31
PMID 30059813
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Breast cancer (BC) is one of the most common malignancies among women worldwide, which is indeed associated with metabolic reprogramming. However, BC is a very complex and heterogeneous disease, which can relate with the changes in metabolic profiles during BC progression. Hence, investigating the metabolic alterations during BC stage progression may reveal the deregulated pathways and useful metabolic signatures of BC. To demonstrate the metabolic insights, we opted H NMR spectroscopy based metabolomics of blood plasma of early and late stage BC (N = 72) with age and gender matched healthy subjects (N = 50). Further, the metabolic profiles were analyzed to delineate the potential signatures of BC by performing multivariate and nonparametric statistical analysis in early and late stages of BC in comparison with healthy subjects. Sixteen metabolites levels were differentially changed (p < 0.05) in the early and late stages of BC from healthy subjects. Among them, the levels of hydroxybutyrate, lysine, glutamate, glucose, N-acetyl glycoprotein, Lactate were highly distinguished in BC stages and showed a good biomarker potential using receiver-operating curves based diagnostic models. Furthermore, the significant modulation and good diagnostic performances of glutamate, N-acetyl glycoprotein and Lactate in LBC as compared to EBC give their significance in the BC progression. In general, our observations demonstrate that these panels of metabolites may act as vital component of the metabolism of early to late stage BC progression. Our results also open new avenue towards early and late stage BC diagnosis and intervention implying metabolomics approaches.

Citing Articles

Serum metabolite and metal ions profiles for breast cancer screening.

Wojtowicz W, Tarkowski R, Olczak A, Szymczycha-Madeja A, Pohl P, Maciejczyk A Sci Rep. 2024; 14(1):24559.

PMID: 39426973 PMC: 11490637. DOI: 10.1038/s41598-024-73097-1.


Metabolomic Profiling of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy for Predicting Disease-Free and Overall Survival.

Talarico M, Derchain S, da Silva L, Sforca M, Rocco S, Cardoso M Int J Mol Sci. 2024; 25(16).

PMID: 39201325 PMC: 11354796. DOI: 10.3390/ijms25168639.


Largescale multicenter study of a serum metabolite biomarker panel for the diagnosis of breast cancer.

Wang Y, An R, Yu H, Dai Y, Lou L, Quan S iScience. 2024; 27(7):110345.

PMID: 39055906 PMC: 11269948. DOI: 10.1016/j.isci.2024.110345.


MR spectroscopy in breast cancer metabolomics.

Sharma U, Jagannathan N Anal Sci Adv. 2024; 2(11-12):564-578.

PMID: 38715862 PMC: 10989566. DOI: 10.1002/ansa.202000160.


Non-targeted metabolomics analysis of indoleamine 2,3-dioxygenase inhibitor treatment in a mouse model of early-stage lung adenocarcinoma.

Xu M, Chen J, Peng C, Mo L Transl Cancer Res. 2024; 13(2):900-915.

PMID: 38482400 PMC: 10928624. DOI: 10.21037/tcr-23-1236.